Cargando…

The durability of sitagliptin in elderly patients with type 2 diabetes

AIM: To evaluate the durability of sitagliptin and to assess changes in clinical chronic complications following sitagliptin monotherapy for 48 months in elderly patients with type 2 diabetes mellitus (T2DM). SUBJECTS AND METHODS: We enrolled 76 drug-naïve patients (40 women and 36 men; mean age: 71...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsieh, Ching-Jung, Shen, Feng-Chih
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232051/ https://www.ncbi.nlm.nih.gov/pubmed/25422588 http://dx.doi.org/10.2147/CIA.S72396

Ejemplares similares

Effect of sitagliptin on proteinuria in patients with type 2 diabetes – A renoprotective effect of sitagliptin
por: Narimani, Rouhollah, et al.
Publicado: (2021)

Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study
por: Ku, Eu Jeong, et al.
Publicado: (2015)

Chitosan oligosaccharide improves the therapeutic efficacy of sitagliptin for the therapy of Chinese elderly patients with type 2 diabetes mellitus
por: Zhao, Lijie, et al.
Publicado: (2017)

Efficacy and Safety of Sitagliptin in Japanese Patients With Type 2 Diabetes
por: Ohmura, Hirotoshi, et al.
Publicado: (2015)

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
por: Omoto, Seitaro, et al.
Publicado: (2015)

Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia
por: Fukuda, Masahiro, et al.
Publicado: (2018)

Sitagliptin and oral cancer risk in type 2 diabetes patients
por: Tseng, Chin-Hsiao
Publicado: (2017)

Sitagliptin and heart failure hospitalization in patients with type 2 diabetes
por: Tseng, Chin-Hsiao
Publicado: (2016)

Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus
por: Shigematsu, Erina, et al.
Publicado: (2014)

Pleiotropic Effects of Sitagliptin in the Treatment of Type 2 Diabetes Mellitus Patients
por: Kubota, Akira, et al.
Publicado: (2012)

Genome-Wide Transcriptome Analysis in Type 2 Diabetes Patients Treated by Sitagliptin
por: Ma, Rui, et al.
Publicado: (2022)

Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus
por: Mori, Hiroko, et al.
Publicado: (2013)

Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus
por: Zeng, De-kang, et al.
Publicado: (2019)

The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes
por: Kodera, Ryo, et al.
Publicado: (2017)

Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes
por: Tseng, Chin-Hsiao
Publicado: (2016)

Severity of hearing impairment is positively associated with urine albumin excretion rate in patients with type 2 diabetes
por: Shen, Feng-Chih, et al.
Publicado: (2014)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: A population-based cohort study
por: Hung, Yi-Chih, et al.
Publicado: (2016)

Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2019)

Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide Cohort Study
por: Chen, Dong-Yi, et al.
Publicado: (2015)

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
por: Tatosian, Daniel A., et al.
Publicado: (2013)

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
por: Miller, Sam, et al.
Publicado: (2018)

Effect of Sitagliptin on Serum Irisin Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Wang, Qiu, et al.
Publicado: (2021)

CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece
por: Ghetti, Gianni, et al.
Publicado: (2023)

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
por: Williams-Herman, Debora, et al.
Publicado: (2008)

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
por: Engel, Samuel S, et al.
Publicado: (2013)

Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
por: Kim, Hyun Min, et al.
Publicado: (2015)

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination
por: Shimoda, Seiya, et al.
Publicado: (2013)

Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea
por: Kubota, Akira, et al.
Publicado: (2014)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
por: Miller, Shannon A, et al.
Publicado: (2009)

Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
por: Engel, Samuel S., et al.
Publicado: (2013)

Efficacy of Initial Basal-Supported Oral Therapy with Sitagliptin in Untreated Type 2 Diabetes
por: Yoshioka, Keiji
Publicado: (2013)

Effects of sitagliptin as initial therapy in newly diagnosed elderly type 2 diabetics: A randomized controlled study
por: Xiao, Xiaoyan, et al.
Publicado: (2016)

Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study
por: Umezawa, Shinichi, et al.
Publicado: (2015)

Efficacy of Combination Therapy With Sitagliptin and Low-Dose Glimepiride in Japanese Patients With Type 2 Diabetes
por: Ishii, Hiroaki, et al.
Publicado: (2014)

Effect of sitagliptin and glimepiride on C-reactive protein (CRP) in overweight Type-2 diabetic patients
por: Hussain, Mazhar, et al.
Publicado: (2019)

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin
por: Kaku, Kohei, et al.
Publicado: (2021)

Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes
por: Tseng, Chin-Hsiao
Publicado: (2016)

Regulation of Adropin by Sitagliptin monotherapy in participants with newly diagnosed type 2 Diabetes
por: Wang, Qiu, et al.
Publicado: (2022)

Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan
por: Wang, Szu-Heng, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lpcendrai3firvmps6p6mtuci0